Drug combination acts against aggressive chronic lymphocytic leukemia

A two-prong approach combining ibrutinib and rituximab (Rituxin®) to treat aggressive chronic lymphocytic leukemia (CLL) produced profound responses with minor side effects in a Phase 2 clinical trial at The University of Texas MD Anderson Cancer Center. Researchers presented the results at the 54th annual meeting of the American Society of Hematology (ASH). Read more here.